• Pacific Edge released the chair’s address transcript from its 2026 annual shareholders’ meeting attended in Auckland and online.
• Chair Simon Flood flagged Novitas’ May draft Medicare LCD proposing coverage for Cxbladder Triage and Triage Plus in hematuria evaluation.
• The draft LCD would make those tests the only biomarkers reimbursable under the policy, with a final LCD expected before year-end.
• Flood put the annual revenue opportunity at USD 10.2 billion, citing millions of US hematuria evaluations each year.
• He said FY26 revenue and volumes fell during Medicare non-coverage, while Triage Plus pricing could lift revenue per reimbursed test.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacific Edge Limited published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein.